顺铂联合紫杉醇脂质体治疗晚期肺鳞癌临床观察.docVIP

顺铂联合紫杉醇脂质体治疗晚期肺鳞癌临床观察 　　【摘要】 目的：观察评价顺铂联合紫杉醇脂质体一线治疗晚期肺鳞癌的疗效和毒性反应。方法：选取2011年4月-2014年8月经病理组织学确诊的84例Ⅲ～Ⅳ期肺鳞癌患者，采用顺铂联合紫杉醇脂质体方案进行一线治疗，化疗至少2个周期后分别按照RECIST 1.1和CTC 3.0标准评价疗效和不良反应。结果：84例患者共完成168个周期化疗，均可评价疗效和毒性反应，最终完全缓解6例，部分缓解32例，有效率为45.2%（38/84）。主要毒副反应为白细胞减少及血小板减少，但均可耐受。化疗后，8.3%患者的KPS评分增加≥10分，15.5%患者体重增加2 kg以上，20.2%患者症状改善。结论：顺铂联合紫杉醇脂质体一线治疗晚期肺鳞癌具有较好的疗效，毒副反应轻，患者易于耐受，值得临床推广应用。 　　【关键词】 非小细胞肺癌； 紫杉醇脂质体； 顺铂； 化学治疗 　　Combinational Therapeutic Efficacy of Cisplatin and Liposomal Paclitaxel in the First Line Treatment of Advanced Lung Squamous Cell Cancer/WU Yun-li， HUANG Jing， WANG Wei-wei， et al.//Medical Innovation of China，2016，13（04）：131-133 　　【Abstract】 Objective： To observe and evaluate combinational therapeutic efficacy and side effects of cisplatin and liposomal paclitaxel in the first line treatment of advanced lung squamous cell cancer patients. Method： Eighty-four advanced （stage： Ⅲ-Ⅳ） lung squamous cell cancer patients were enrolled and pathological diagnosis were all verified. After 2 cycles of cisplatin and liposomal paclitaxel combinational treatment， we evaluated efficacy and side effects based on RECIST 1.1 and CTC 3.0. Result： Eighty-four patients accomplished 168 cycles treatment in total and that satisfied statistically analysis. Response rate was 45.2% （38/84）， which contained 6 cases of CR， 32 cases of PR. The main side effects was leukocytopenia and thrombocytopenia. 8.3% patients gained more than 10 points in KPS evaluation， 15.5% patients gained more than 2 kg in weight， and 20.2% patients lived with improved clinical symptoms. Conclusion： Combinational therapy of cisplatin and liposomal paclitaxel show promising short term effect in the treatment of advanced lung squamous cell cancer patients with less and more tolerable side effects. 　　【Key words】 NSCLC； Liposomal paclitaxel； Cisplatin； Chemotherapy 　　First-author’s address： NO.3 Affiliated Hospital of Kunming Medical University， Yunnan Provincial Tumor Hospital， Kunming 650112， China 　　doi：10.3969/j.